Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.
Cardiol Therapeutics (CRDL) filed a Form 6-K furnishing a news release as Exhibit 99.1. The exhibit, dated October 21, 2025, states the company completed a US$11.4 million financing and extended its cash runway into Q3 2027.
This is an informational submission under the Exchange Act for foreign private issuers and directs readers to the attached news release for details.
Cardiol Therapeutics (CRDL) furnished a Form 6‑K that includes a news release titled “Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027.” The filing signals that the company has secured US$11 million in financing, which the company states extends its cash runway into Q3 2027. Details of the structure or terms are contained in the referenced news release.
Cardiol Therapeutics Inc., a foreign private issuer based in Oakville, Ontario, furnished a Form 6-K indicating it files annual reports on Form 40-F. The report primarily submits a news release announcing Cardiol’s participation in a fireside chat at Canaccord Genuity’s 45th Annual Growth Conference.